| Literature DB >> 33733417 |
Deepak Panchal1,2, Om Prakash2, Prakash Bobde2,3, Sukdeb Pal4,5.
Abstract
Transmission of novel coronavirus (SARS-CoV-2) in humans happens either through airway exposure to respiratory droplets from an infected patient or by touching the virus contaminated surface or objects (fomites). Presence of SARS-CoV-2 in human feces and its passage to sewage system is an emerging concern for public health. Pieces of evidence of the occurrence of viral RNA in feces and municipal wastewater (sewage) systems have not only warned reinforcing the treatment facilities but also suggest that these systems can be monitored to get epidemiological data for checking trend of COVID-19 infection in the community. This review summarizes the occurrence and persistence of novel coronavirus in sewage with an emphasis on the possible water environment contamination. Monitoring of novel coronavirus (SARS-CoV-2) via sewage-based epidemiology could deliver promising information regarding rate of infection providing a valid and complementary tool for tracking and diagnosing COVID-19 across communities. Tracking the sewage systems could act as an early warning tool for alerting the public health authorities for necessary actions. Given the impracticality of testing every citizen with limited diagnostic resources, it is imperative that sewage-based epidemiology can be tested as an early warning system. The need for the development of robust sampling strategies and subsequent detection methodologies and challenges for developing countries are also discussed.Entities:
Keywords: COVID-19; Coronavirus; SARS-CoV-2; Sewage; Surveillance; Transmission
Mesh:
Substances:
Year: 2021 PMID: 33733417 PMCID: PMC7968922 DOI: 10.1007/s11356-021-13170-8
Source DB: PubMed Journal: Environ Sci Pollut Res Int ISSN: 0944-1344 Impact factor: 4.223
Fig. 1Occurrence, transmission, fate of Coronavirus in community
Potential biomarker used for monitoring infectious disease
| Biomarker | Example | Indicator of | Reference |
|---|---|---|---|
Chemical: Drug and metabolites | Azithromycin n-Demethyl azithromycin | intestinal infections and middle ear infections, Pneumonia, strep throat and | Senta et al. |
| Ciprofloxacin | Respiratory tract and skin infections, gastroenteritis | Guerra et al. | |
Clarithromycin | skin infections, pneumonia, and Lyme disease. | Senta et al. | |
Sulfamethoxazole | Bronchitis and Urinary tract infections | Hijosa-Valsero et al. | |
| Erythromycin | Respiratory tract infections | Kasprzyk-Hordern et al. | |
Oseltamivir phosphate | Flu virus (influenza) | Leknes et al. | |
| Zanamivir | TAKANAMI et al. | ||
| Clotrimazole | Skin and vaginal infections | Huang et al. | |
| Acetaminophen | Painkiller | Guerra et al. | |
| Ibuprofen | Guerra et al. | ||
| Interlukin-8 (IL-8) | Inflammation in urinary tract infections | Taha et al. | |
| C-reactive protein (CRP) | Inflammation | Stuveling et al. | |
Biological: Pathogenic bacterial DNA, viral RNA/DNA and Antibiotic resistant genes | UTI, Pneumonia, bacteremia and endophthalmitis | Shannon et al. | |
| Norovirus (GI) | Gastroenteritis | Hellmér et al. | |
| Zika | Mild infection, microcephaly | Gourinat et al. | |
| Methicillin resistance | Börjesson et al. | ||
| Erythromycin resistance | Wang et al. | ||
| Tetracycline resistance | Wang et al. |
Possible diagnostics emerged for SARS-CoV-2
| Tests | Biomarkers | Working principle | Reference |
|---|---|---|---|
| Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) | Nucleic acid | PCR, CRISPR/Ca9-mediated lateral flow nucleic assay (CASLFA) | Wang et al. |
| CRISPR | RPA, CRISPR- Cas13- or Cas12-mediated detection via fluorescent and colorimetric readouts | Kellner et al. | |
| Loop-mediated isothermal amplification (LAMP) | isothermal DNA synthesis using self-recurring strand displacement reactions; sample gets turbid on positive test | Imai et al. | |
| Recombinase polymerase amplification (RPA) | forward and reverse primers bind to DNA and amplification occurs at 37 °C | Amer et al. | |
| Feluda test (Paper Based Approach) | Based on cutting-edge gene-editing CRISPR-CAS-9 technology | Azhar et al. | |
| CDC SARS-CoV-2 qRT–PCR | transcription-based amplification for RNA targets | CDC | |
| Nucleic acid sequence-based amplification (NASBA) | RNA targets amplification (transcription) | Wat et al. | |
| Rolling circle amplification RCA | DNA polymerase extend the circular primer and replicate the sequence repeatedly | Martel et al. | |
| Abbott ID NOW COVID-19 | PCR isothermal test amplifying virus genome | Abbott | |
| RT-LAMP | reverse transcriptase LAMP reaction for RNA targets | Shirato et al. | |
| SARS-CoV-2 DETECTR assay | lateral flow assay: CRISPR–Cas12-based | Broughton et al. | |
| Quantum dot barcode | RPA detection of captured viral DNA via multiplexed quantum beads | Kim et al. | |
| Magnetic bead | Bacteria isolated by magnetic beads for PCR detection | Nilsson et al. | |
| Smartphone dongle | Protein | cassette operating an ELISA (microfluidics-based) | Laksanasopin et al. |
| Paramagnetic bead | magnetic separation of protein targets | Aytur et al. | |
| ELISA | enzymatic reaction producing colored product when target is present | Rowe et al. | |
| Simoa | digital readout of colored product by enzymatic reaction when target present | Rissin et al. | |
| Biobarcode assay | protein signal is indirectly linked and detected by amplifying DNA conjugated to gold nanoparticle | Thaxton et al. | |
| Rapid antigen test | gold-coated antibodies give colorimetric test in the presence of target | Bosch et al. | |
| Magnetic bead isolation | Whole bacteria | magnetic isolation of bacteria | Bicart-See et al. |
Sewage generation, treatment capacity, and service level in India (ENVIS 2019*; CPCB 2020$)
| Sewage Generation* (× 1000 MLD) | Available treatment capacity* (× 1000 MLD) [% of total generation] | Service level* (× 1000 MLD) [% of available capacity] | Service Level* (× 1000 MLD) [% of total generation] | Plants | Surface water criteria$-total coliforms (MPN/100 mL) |
|---|---|---|---|---|---|
| 62 | 23 [37] | 19 [81.1] | 19 [30] | 39 | 500–5000 |